DE19645361A1 - Production of epothilone compounds with taxol-like activity - Google Patents

Production of epothilone compounds with taxol-like activity

Info

Publication number
DE19645361A1
DE19645361A1 DE19645361A DE19645361A DE19645361A1 DE 19645361 A1 DE19645361 A1 DE 19645361A1 DE 19645361 A DE19645361 A DE 19645361A DE 19645361 A DE19645361 A DE 19645361A DE 19645361 A1 DE19645361 A1 DE 19645361A1
Authority
DE
Germany
Prior art keywords
mmol
solution
benzyl
epothilone
tetrahydropyranyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19645361A
Other languages
German (de)
Inventor
Dieter Schinzer
Anja Limberg
Olivar M Boehm
Armin Bauer
Martin Cordes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19636343A external-priority patent/DE19636343C1/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to DE19645361A priority Critical patent/DE19645361A1/en
Priority to NZ334821A priority patent/NZ334821A/en
Priority to PCT/DE1997/000111 priority patent/WO1998008849A1/en
Priority to AU21493/97A priority patent/AU716610B2/en
Priority to JP10511141A priority patent/JP2001500851A/en
Priority to EP97914077A priority patent/EP0923583A1/en
Priority to US08/921,512 priority patent/US5969145A/en
Publication of DE19645361A1 publication Critical patent/DE19645361A1/en
Priority to US09/344,713 priority patent/US6043372A/en
Priority to US09/478,466 priority patent/US6156905A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)

Abstract

Production of epothilone A and B of formula (I) comprises esterification of a thiazolyl-hydroxyalkyldiene (II) with a protected 3,7-dihydroxy-5-oxo-tridecenoic acid (III) and conversion of the resulting ester into (I) by the following sequence of reactions: (a) ring closure involving olefin metathesis in the presence of a noble metal catalyst; (b) optional deprotection of protected hydroxy groups, (c) epoxidation and (d) deprotection of protected hydroxy groups as required. R = H (epothilone A) or Me (epothilone B); B = benzyl; tetrahydropyranyl; or silyl protecting group. Also claimed are starting materials (II) and (III) and desoxy-epothilone intermediates (IV) (obtained from step (a) and optionally (b)): B1 = H; benzyl; p-methoxybenzyl; tetrahydropyranyl; or silyl protecting group. Further claimed are 2-(2,2-dimethyl-1,3dioxan-4-yl)-2-methyl-pentan-3-one (V); 2-methyl-6-heptenal (VI), 2,6-dimethyl-6-heptenal (VII) and (4S,6S)-2-(2,2-dimethyl-1,3-dioxan-4-yl)-5-hydroxy-2,4,6-trimethyl-und ecan-3-one (sic) (DDHTU); used for the preparation of (III); as well as protected thiazolyl-hydroxyalkyldienes (VIII) used for the preparation of (II): B2 = benzyl; p-methoxybenzyl; tetrahydropyranyl; or silyl protecting group. Note - The final claim appears to cover stereoisomers of all the above compounds except (DDHTU) and (VIII) sic; the phrasing of the claims is ambiguous. (I) are known from DE 4138042.

Description

Die Erfindung betrifft Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B.The invention relates to intermediates within the total synthesis of epothilone A and B.

Epothilon A und B sind Naturstoffe, die durch Mikroorganismen hergestellt werden können und die Taxol ähnliche Eigenschaften besitzen und somit besonderes Interesse in der Arzneimittelchemie besitzen. Diese Epothilone A und B werden innerhalb des Standes der Technik in DE 41 38 042 C2 und in European Chemistry Chronicle, Vol. 1/No. 1 S. 7-10 beschrieben.Epothilon A and B are natural products that are produced by microorganisms can and the Taxol have similar properties and therefore special Interest in drug chemistry. These are epothilones A and B. within the state of the art in DE 41 38 042 C2 and in European Chemistry Chronicle, Vol. 1 / No. 1 pp. 7-10.

Aufgabe der vorliegenden Erfindung ist es, Zwischenprodukte für die Totalsynthese von Epothilon A und B bereitzustellen, die es erlauben, die Naturstoffe einfach herzustellen und ebenso die Strukturen in der üblichen Art und Weise zu variieren, um Verbindungen mit stärkeren bzw. nebenwirkungsärmeren Eigenschaften herstellen zu können.The object of the present invention is to provide intermediates for total synthesis of epothilones A and B, which allow the natural products to be easily to manufacture and also to vary the structures in the usual way, to compounds with stronger or less side effects to be able to manufacture.

Die Erfindung beinhaltet Verbindungen der allgemeinen Formel 2a
The invention includes compounds of the general formula 2a

worin A = Wasserstoff oder eine niedrige Alkylgruppe (Methyl, Ethyl, Propyl, Iso- Propyl, Butyl-, iso- und ter. Butyl)) und B = Wasserstoff, Benzyl-, Tetrahydro­ pyranyl- oder eine Silylschutzgruppe (beispielsweise Trimethyl-, tert.-Buty­ dimethyl-, Diphenyl-tert.-butyl-silyl) bedeutet. where A = hydrogen or a lower alkyl group (methyl, ethyl, propyl, iso- Propyl, butyl, iso and ter. Butyl)) and B = hydrogen, benzyl, tetrahydro pyranyl or a silyl protective group (for example trimethyl, tert-buty dimethyl-, diphenyl-tert-butyl-silyl) means.  

Weiter beinhaltet die Erfindungen Verbindungen der allgemeinen Formel 2b
The inventions furthermore comprise compounds of the general formula 2b

worin A = Wasserstoff oder eine niedrige Alkylgruppe (C1-C4) und B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeutet. Die Bedeutung von B im Molekül kann unterschiedlich sein kann.wherein A = hydrogen or a lower alkyl group (C 1 -C 4 ) and B = hydrogen, benzyl, tetrahydropyranyl or a silyl protective group. The meaning of B in the molecule can be different.

Weiter beinhaltet die Erfindung 2-Methyl-6-heptenal 4a
The invention further includes 2-methyl-6-heptenal 4a

und Verbindungen der allgemeinen Formel 8a
and compounds of general formula 8a

worin B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeutet und die Bedeutung von B im Molekül ebenfalls unterschiedlich sein können und Verbindungen der allgemeinen Formel 8b
where B = hydrogen, benzyl, tetrahydropyranyl or a silyl protective group and the meaning of B in the molecule can also be different and compounds of the general formula 8b

worin B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeutet und die Bedeutung von B im Molekül unterschiedlich sein kann weiter werden die Stereoisomere der Verbindungen umfaßt. where B = hydrogen, benzyl, tetrahydropyranyl or a silyl protecting group means and the meaning of B in the molecule can be different the stereoisomers of the compounds are further included.  

Synthese von Segment 4Synthesis of segment 4

Arbeitsvorschriften zur Darstellung von Segment 4Work regulations for the presentation of segment 4

Das Natrium-6-hydroxyhexanoat 20 wird nach einer Vorschrift von Wulff, Krüger und Röhle Chem. Ber. 1971, 104, 1387-1399 [6] aus w-Caprolacton 19 hergestellt.The sodium 6-hydroxyhexanoate 20 is produced according to a regulation by Wulff, Krüger and Röhle Chem. Ber. 1971, 104, 1387-1399 [6] made from w-caprolactone 19.

Darstellung von 6-[(tert-Butyldimethylsilyl)oxy]-hexansäuresilylester 21 [7] Preparation of 6 - [(tert-butyldimethylsilyl) oxy] hexanoic acid silyl ester 21 [7]

Eine Mischung aus 2.00 g (12.97 mmol) des Salzes 20, 25 ml DMF, 5.87 g (38.93 mmol, 3 equiv) TBDMSCl und 5.3 g (77.85 mmol, 6 equiv) Imidazol wird 48 Stunden bei RT gerührt. Das Reaktionsgemisch wird flashfiltriert und anschließend mit Pentan:DE = 4 : 1 säulen-chromatographisch gereinigt. Man erhält 3.99 g (11.1 mmol) der bissilylierten Verbindung 21, entsprechend einer Ausbeute von 85%.
Allgemeine Daten: C18H40O3Si2, FG = 360.69 g/mol
13C-NMR (100 MHz, CDCl3): 174.17 (s), 63.00 (t), 36.02 (t), 32.53 (t), 25.95 (q), 25.55 (q), 25.40 (t), 24.91(t), 18.33 (s), 17.57 (s), -4.83(q), -5.32(q)A mixture of 2.00 g (12.97 mmol) of the salt 20, 25 ml of DMF, 5.87 g (38.93 mmol, 3 equiv) TBDMSCl and 5.3 g (77.85 mmol, 6 equiv) imidazole is stirred for 48 hours at RT. The reaction mixture is flash filtered and then purified by column chromatography with pentane: DE = 4: 1. 3.99 g (11.1 mmol) of the bissilylated compound 21 are obtained, corresponding to a yield of 85%.
General data: C 18 H 40 O 3 Si 2 , FG = 360.69 g / mol
13 C-NMR (100 MHz, CDCl 3 ): 174.17 (s), 63.00 (t), 36.02 (t), 32.53 (t), 25.95 (q), 25.55 (q), 25.40 (t), 24.91 (t ), 18.33 (s), 17.57 (s), -4.83 (q), -5.32 (q)

Darstellung von 6-[(tert-Butyldimethylsilyl)oxy]-hexansäure 22 nach D.R. Morton, J.L. Thompson, J. Org. Chem. 1978, 43, 2102-2106 [8] Preparation of 6 - [(tert-butyldimethylsilyl) oxy] hexanoic acid 22 according to DR Morton, JL Thompson, J. Org. Chem. 1978, 43, 2102-2106 [8]

Eine Lösung von 3.25 g (9.02 mmol) der bissilylierten Verbindung 21 in 130 ml Methanol und 44 ml THF wird mit einer Lösung von 4.4 g (31.8 mmol, 3.5 equiv) K2CO3 in 44 ml H2O versetzt und 1 h bei RT gerührt. Danach wird das Volumen der Reaktionslösung im Vakuum auf ein Viertel reduziert. Man verdünnt mit 130 ml ges. NaCl-Lösung und stellt mit 1 M KHSO4-Lösung auf pH 4-5 ein. Es wird mit Diethylether extrahiert. Die vereinigten organischen Phasen werden über MgSO4 getrocknet und das Lösungsmittel am Rotationsverdampfer abdestilliert. Man erhält 2.01 g (8.17 mmol) der Carbonsäure 22, entsprechend einer Ausbeute von 90%.
Allgemeine Daten: C12H26O3Si, FG = 246.42 g/mol
13C-NMR (100 MHz, CDCl3): 180.09 (s), 62.90 (t), 34.05 (t), 32.37 (t), 25.93 (q), 25.31(t), 24.46 (t), 18.32 (s), -5.33(q) A solution of 3.25 g (9.02 mmol) of the bissilylated compound 21 in 130 ml of methanol and 44 ml of THF is mixed with a solution of 4.4 g (31.8 mmol, 3.5 equiv) of K 2 CO 3 in 44 ml of H 2 O and added for 1 h RT stirred. The volume of the reaction solution is then reduced to a quarter in vacuo. It is diluted with 130 ml of sat. NaCl solution and adjust to pH 4-5 with 1 M KHSO 4 solution. It is extracted with diethyl ether. The combined organic phases are dried over MgSO 4 and the solvent is distilled off on a rotary evaporator. 2.01 g (8.17 mmol) of carboxylic acid 22 are obtained, corresponding to a yield of 90%.
General data: C 12 H 26 O 3 Si, FG = 246.42 g / mol
13 C-NMR (100 MHz, CDCl 3 ): 180.09 (s), 62.90 (t), 34.05 (t), 32.37 (t), 25.93 (q), 25.31 (t), 24.46 (t), 18.32 (s ), -5.33 (q)

Darstellung von 6-[(tert.Butyldimethylsilyl)oxy]-hexanoylchlorid 23, J. Tanaka, Bull Chem. Jpn. 1992, 65, 2851-2853 [9] Preparation of 6 - [(tert-butyldimethylsilyl) oxy] hexanoyl chloride 23, J. Tanaka, Bull Chem. Jpn. 1992, 65, 2851-2853 [9]

Eine Lösung von 0.5 g (2.03 mmol) Carbonsäure in 4 ml Benzol wird mit 362 mg (3.04 mmol, 1.5 equiv) SOCl2 versetzt und 2 h unter Rückfluß erhitzt. Man läßt abkühlen und destilliert das Lösungsmittel am Rotationsverdampfer ab. Um das überschüssige SOCl2 aus der Reaktionsmischung zu entfernen, wird der Rückstand wieder mit Benzol versetzt und erneut abdestilliert. Man erhält 494 mg (1.865 mmol, 92%) des Säurechlorids 23. Dieses Rohprodukt wird ohne Aufreinigung und Charakterisierung weiter umgesetzt.A solution of 0.5 g (2.03 mmol) carboxylic acid in 4 ml benzene is mixed with 362 mg (3.04 mmol, 1.5 equiv) SOCl 2 and heated under reflux for 2 h. The mixture is allowed to cool and the solvent is distilled off on a rotary evaporator. In order to remove the excess SOCl 2 from the reaction mixture, the residue is mixed again with benzene and distilled off again. 494 mg (1,865 mmol, 92%) of the acid chloride 23 are obtained. This crude product is reacted further without purification and characterization.

Darstellung von 3-[6-[(tert-Butyldimethylsilyl)oxy]-hexanoyl]-4-isopropyl­ oxazolidin-2-on 7, A. Gonzalez, Synth. Comm. 1991, 21, 1353-1360 [10] Preparation of 3- [6 - [(tert-butyldimethylsilyl) oxy] hexanoyl] -4-isopropyl oxazolidin-2-one 7, A. Gonzalez, Synth. Comm. 1991, 21, 1353-1360 [10]

Eine Lösung von 755 mg (5.845 mmol) (4S)-4-(1-Methylethyl)-2-oxazolidinon 24 in 8 ml THF wird auf -78°C gekühlt und tropfenweise mit 4.0 ml (6.43 mmol, 1.1 equiv) einer n-BuLi-Lösung (1.6 M in Hexan) versetzt. Anschließend wird bei -78°C innerhalb von 2 Minuten eine Lösung von 1.703 g (6.43 mmol, 1.1 equiv) Säurechlorid 23 in 7 ml THF zugegeben. Man läßt auf RT erwärmen und versetzt mit 11 ml einer 1 M wäßrigen K2CO3-Lösung und läßt 15 Minuten rühren. Es wird mit CH2Cl2 extrahiert, über MgSO4 getrocknet und das Lösungsmittel am Rotationsverdampfer abdestilliert. Der Rückstand wird säulen-chromatographisch mit Pentan:DE = 1 : 1 gereinigt. Man erhält 1.352 g (3.78 mmol) der Verbindung 7, entsprechend einer Ausbeute von 65%.
Allgemeine Daten: C18H35NO4Si, FG = 357.56 g/mol
13C-NMR (100 MHz, CDCl3): 173.22 (s), 154.02 (s), 63.26 (t), 62.94 (t), 58.32 (d), 35.47 (t), 32.52 (t), 28.32 (d), 25.92 (q), 25.36 (t), 24.18 (t), 18.29 (s), 17.92 (q), 14.61(q), -5.34(q) A solution of 755 mg (5,845 mmol) of (4S) -4- (1-methylethyl) -2-oxazolidinone 24 in 8 ml of THF is cooled to -78 ° C and added dropwise with 4.0 ml (6.43 mmol, 1.1 equiv) of a n -BuLi solution (1.6 M in hexane) added. A solution of 1,703 g (6.43 mmol, 1.1 equiv) of acid chloride 23 in 7 ml of THF is then added at -78 ° C. in the course of 2 minutes. The mixture is allowed to warm to RT and 11 ml of a 1 M aqueous K 2 CO 3 solution are added and the mixture is stirred for 15 minutes. It is extracted with CH 2 Cl 2 , dried over MgSO 4 and the solvent is distilled off on a rotary evaporator. The residue is purified by column chromatography with pentane: DE = 1: 1. 1,352 g (3.78 mmol) of compound 7 are obtained, corresponding to a yield of 65%.
General data: C 18 H 35 NO 4 Si, FG = 357.56 g / mol
13 C-NMR (100 MHz, CDCl 3 ): 173.22 (s), 154.02 (s), 63.26 (t), 62.94 (t), 58.32 (d), 35.47 (t), 32.52 (t), 28.32 (d ), 25.92 (q), 25.36 (t), 24.18 (t), 18.29 (s), 17.92 (q), 14.61 (q), -5.34 (q)

Darstellung von 3-[6-[(tert-Butyldimethylsilyl)oxy]-2-methyl-hexanoyl]-4- isopropyl-oxazolidin-2-on 25, D.A. Evans, A.E. Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 [11] Preparation of 3- [6 - [(tert-butyldimethylsilyl) oxy] -2-methyl-hexanoyl] -4-isopropyl-oxazolidin-2-one 25, Evans DA, AE Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 [11]

Es werden 1.231 ml (1.231 mmol, 1.1 equiv) einer 1 M Lösung von NaHMDS in THF auf -78°C gekühlt und tropfenweise mit einer auf 0°C gekühlten Lösung von 400 mg (1.119 mmol) Oxazolidinon 7 in 3.5 ml THF versetzt. Man läßt 30 Minuten bei -78°C rühren, addiert 793 mg (5.593 mmol, 5 equiv) Mel gelöst in 2 ml THF und läßt für 4 h bei -78°C rühren. Anschließend wird mit ges. NH4Cl-Lösung gequencht, mit Diethylether extrahiert, über MgSO4 getrocknet und eingeengt. Der Rückstand wird säulenchromatographisch mit Pentan:DE = 2 : 1 gereinigt, wobei das in geringem Maße entstandene unerwünschte Diastereomer leicht abgetrennt werden kann. Man erhält 328 mg (0.917 mmol) des methylierten Produkts 25, entsprechend einer Ausbeute von 82%.
Allgemeine Daten: C19H37NO4Si, FG = 371.59 g/mol
13C-NMR (100 MHz, CDCl3): 177.13 (s), 153.60 (s), 63.13 (t), 62.95 (t), 58.38 (d), 37.63 (d), 32.83 (t), 32.78 (t), 28.37 (d), 25.92 (q), 23.50 (t), 18.29 (s), 17.89 (q), 17.76 (q), 14.63 (q), -5.33(q)1,231 ml (1,231 mmol, 1.1 equiv) of a 1 M solution of NaHMDS in THF are cooled to -78 ° C and a solution of 400 mg (1,119 mmol) oxazolidinone 7 in 3.5 ml THF, cooled to 0 ° C, is added dropwise. The mixture is stirred at -78 ° C. for 30 minutes, 793 mg (5,593 mmol, 5 equiv) of Mel dissolved in 2 ml of THF are added and the mixture is stirred at -78 ° C. for 4 h. Then with sat. Quenched NH 4 Cl solution, extracted with diethyl ether, dried over MgSO 4 and concentrated. The residue is purified by column chromatography with pentane: DE = 2: 1, the undesirable diastereomer which has formed to a small extent being able to be separated off easily. 328 mg (0.917 mmol) of the methylated product 25 are obtained, corresponding to a yield of 82%.
General data: C 19 H 37 NO 4 Si, FG = 371.59 g / mol
13 C-NMR (100 MHz, CDCl 3 ): 177.13 (s), 153.60 (s), 63.13 (t), 62.95 (t), 58.38 (d), 37.63 (d), 32.83 (t), 32.78 (t ), 28.37 (d), 25.92 (q), 23.50 (t), 18.29 (s), 17.89 (q), 17.76 (q), 14.63 (q), -5.33 (q)

Darstellung von 6-[(tert-Butyldimethylsilyl)oxy]-2-methyl-hexan-1ol 26, D.A. Evans, A.E. Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 [11] Preparation of 6 - [(tert-Butyldimethylsilyl) oxy] -2-methyl-hexan-1ol 26, DA Evans, AE Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 [11]

Zu einer auf 0°C gekühlten Lösung von 168 mg (0.452 mmol) der Verbindung 25 in 3 ml Diethylether wird über einen Zeitraum von 40 Minuten mit Hilfe einer Dosierpumpe 452 µl (0.452 mmol, 1 equiv) einer 1 M Lösung von LAH in Diethylether zugegeben. Falls sich DC-chromatographisch noch Edukt nachweisen läßt, wird weitere LAH-Lösung zugetropft bis die Umsetzung vollständig ist. Es wird gequencht durch die Zugabe von 17 µl Wasser, 17 µl 15%iger wäßriger NaOH- Lösung und 52 µl Wasser. Anschließend wird über grobes Kieselgel mit Diethylether flashfiltriert und säulenchromatographisch mit Pentan:DE = 1 : 1 gereinigt. Man erhält 94 mg (0.381 mmol) des Alkohols 26, entsprechend einer Ausbeute von 84%.
Allgemeine Daten: C13H30O2Si, FG = 246.46 g/mol
13C-NMR (100 MHz, CDCl3): 68.25 (t), 63.12 (t), 35.72 (d), 33.03 (t), 32.84 (t), 25.94 (q), 23.13 (t), 18.34 (s), 16.51(q), -5.29(q) 452 μl (0.452 mmol, 1 equiv) of a 1 M solution of LAH in diethyl ether is added to a solution of 168 mg (0.452 mmol) of compound 25 in 3 ml of diethyl ether cooled to 0 ° C. over a period of 40 minutes admitted. If starting material can still be detected by TLC, further LAH solution is added dropwise until the reaction is complete. It is quenched by adding 17 µl water, 17 µl 15% aqueous NaOH solution and 52 µl water. It is then flash-filtered over coarse silica gel with diethyl ether and purified by column chromatography with pentane: DE = 1: 1. 94 mg (0.381 mmol) of alcohol 26 are obtained, corresponding to a yield of 84%.
General data: C 13 H 30 O 2 Si, FG = 246.46 g / mol
13 C-NMR (100 MHz, CDCl 3 ): 68.25 (t), 63.12 (t), 35.72 (d), 33.03 (t), 32.84 (t), 25.94 (q), 23.13 (t), 18.34 (see ), 16.51 (q), -5.29 (q)

Darstellung von 6-[(tert-Butyldimethylsilyl)oxy]-2-methyl-hexanal 4, D.A. Evans, A.E. Weber J. Am. Chem. Soc. 1986, 108, 6757--6761 [11] Preparation of 6 - [(tert-Butyldimethylsilyl) oxy] -2-methyl-hexanal 4, DA Evans, AE Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 [11]

Eine Lösung aus 64 mg (0.505 mmol, 1.4 equiv) Oxalylchlorid in 2 ml CH2Cl2 wird auf -78°C gekühlt und 79 mg (1.011 mmol, 12.8 equiv) DMSO addiert. Nach 5 Minuten wird eine Lösung aus 89 mg (0.361 mmol) des Alkohols 26 in 1 ml CH2Cl2 zugetropft. Man läßt 30 Minuten bei -78°C rühren und addiert dann 161 mg (1.589 mmol, 4.4 equiv) NEt3. Man ersetzt das -78°C-Kältebad durch ein -30°C-Bad und läßt eine weitere Stunde rühren. Anschließend wird mit 5.2 ml Pentan verdünnt, mit 3.4 ml einer 1 M wäßrigen NaHSO4-Lösung und 3 mal mit je 3.4 ml Wasser gewaschen, über MgSO4 getrocknet und eingeengt. Der Rückstand wird mit Pentan:DE = 2 : 1 säulenchromatographisch gereinigt. Man erhält 77 mg (0.315 mmol) des Aldehyds 4, entsprechend einer Ausbeute von 87%.
Allgemeine Daten: C13H28O2Si, FG = 244.45 g/mol
13C-NMR (100 MHz, CDCl3): 205.24 (d), 62.81(t), 46.30 (d), 32.73 (t), 30.25 (t), 25.93 (q), 23.25 (t), 18.33 (s), 13.25 (q), -5.32(q)A solution of 64 mg (0.505 mmol, 1.4 equiv) oxalyl chloride in 2 ml CH 2 Cl 2 is cooled to -78 ° C and 79 mg (1.011 mmol, 12.8 equiv) DMSO are added. After 5 minutes, a solution of 89 mg (0.361 mmol) of the alcohol 26 in 1 ml of CH 2 Cl 2 is added dropwise. The mixture is stirred at -78 ° C. for 30 minutes and then 161 mg (1,589 mmol, 4.4 equiv) NEt 3 are added . The -78 ° C cold bath is replaced by a -30 ° C bath and the mixture is stirred for another hour. The mixture is then diluted with 5.2 ml of pentane, washed with 3.4 ml of a 1 M aqueous NaHSO 4 solution and 3 times with 3.4 ml of water each time, dried over MgSO 4 and concentrated. The residue is purified by column chromatography with pentane: DE = 2: 1. 77 mg (0.315 mmol) of aldehyde 4 are obtained, corresponding to a yield of 87%.
General data: C 13 H 28 O 2 Si, FG = 244.45 g / mol
13 C-NMR (100 MHz, CDCl 3 ): 205.24 (d), 62.81 (t), 46.30 (d), 32.73 (t), 30.25 (t), 25.93 (q), 23.25 (t), 18.33 (see ), 13.25 (q), -5.32 (q)

Die Herstellung von 2-Methyl-6-heptenal 4a erfolgt aus der käuflichen 6-Hepten­ säure; es wird analog der Herstellung von 23 das entsprechende Säurechlorid synthetisiert und dann über die beschriebenen Stufen 7 (Oxazolidinon), 25 (Methylierung), 26 (Reduktion mit LAH) und 4 (Oxalylchlorid-Oxidation zum Aldehyd) das 2-Methyl-6-heptenal 4a erhalten. The production of 2-methyl-6-heptenal 4a takes place from the commercially available 6-heptene acid; analogously to the preparation of 23, the corresponding acid chloride synthesized and then via the described steps 7 (oxazolidinone), 25 (Methylation), 26 (reduction with LAH) and 4 (oxalyl chloride oxidation to Aldehyde) receive the 2-methyl-6-heptenal 4a.  

Synthese von Segment 8Synthesis of segment 8

Arbeitsvorschriften zur Synthese von Segment 8: 3-[(t-Butyldimethylsilyl)oxy]-propanal 5Working instructions for the synthesis of segment 8: 3 - [(t-Butyldimethylsilyl) oxy] propanal 5

Synthese durch Monosilylierung von 1,3-Propandiol und anschließende Swern- Oxidation des entstandenen 3-[(t-Butyldimethylsilyl)oxy]-1-propanols.
Allgemeine Daten: C9H20O2Si; FG=188.36; CAS-Nr. [89922-82-7]
13C-NMR (100 MHz, CDCl3): d=202.05 (d), 57.42 (t), 46.58 (t), 25.82 (q), 18.23 (s), -5.43(q) Synthesis by monosilylation of 1,3-propanediol and subsequent Swern oxidation of the resulting 3 - [(t-butyldimethylsilyl) oxy] -1-propanol.
General data: C 9 H 20 O 2 Si; FG = 188.36; CAS number [89922-82-7]
13 C-NMR (100 MHz, CDCl 3 ): d = 202.05 (d), 57.42 (t), 46.58 (t), 25.82 (q), 18.23 (s), -5.43 (q)

1-[(t-Butyldimethylsilyl)oxy]-3-hydroxy-4-methyl-4-penten 271 - [(t-Butyldimethylsilyl) oxy] -3-hydroxy-4-methyl-4-pentene 27

Zu 443 mg Mg-Drehspänen (18.2 mmol) und 1.5 ml abs. THF unter N2 werden 0.2 ml 2-Brompropen gegeben, so daß die Reaktion anspringt. Es wird unter gelegentlicher Kühlung eine Lösung von 1.7 ml 2-Brompropen (insgesamt 22 mmol) in 6 ml abs. THF langsam zugetropft, bis alle Mg-Späne gelöst sind. Zu der noch warmen Mischung wird eine Lösung von 2.862 g 1(15.2 mmol) in 6 ml abs. THF getropft. Es wird 6 h bei RT gerührt. Danach gibt man 25 ml ges. NH4Cl-Lsg. zu der Reaktionslösung und läßt 10 Min. rühren. Die Mischung wird in 30 ml ges. NH4Cl- Lsg. gegossen und zweimal mit Ether extrahiert. Die vereinigten org. Phasen werden je einmal mit ges. NH4Cl-Lsg. und ges. NaCl-Lsg. gewaschen. Man trocknet über MgSO4, engt im Vakuum ein und reinigt flashchromatographisch (Ether:Pentan = 1 : 6).
Man erhält 2.749 g 2 (11.9 mmol; 79% d. Th.) als farbloses Öl.
Allgemeine Daten: C12H26O2Si; FG=230.43
13C-NMR (100 MHz1 CDCl3): d=147.10(s), 110.39(t), 75.21(d), 62.17 (t), 36.79 (t), 25.89 (q), 18.41(s), -5.49(q), -5.53(q)To 443 mg Mg turnings (18.2 mmol) and 1.5 ml abs. THF under N 2 are given 0.2 ml of 2-bromine propene so that the reaction starts. With occasional cooling, a solution of 1.7 ml of 2-bromopropene (22 mmol in total) in 6 ml of abs. THF slowly added dropwise until all Mg chips are dissolved. A solution of 2,862 g 1 (15.2 mmol) in 6 ml abs. THF dropped. The mixture is stirred at RT for 6 h. Then 25 ml of sat. NH 4 Cl solution. to the reaction solution and allowed to stir for 10 minutes. The mixture is sat in 30 ml. Poured NH 4 Cl solution and extracted twice with ether. The united org. Phases are recorded once with sat. NH 4 Cl solution. and sat. NaCl solution. washed. It is dried over MgSO 4 , concentrated in vacuo and purified by flash chromatography (ether: pentane = 1: 6).
2,749 g 2 (11.9 mmol; 79% of theory) are obtained as a colorless oil.
General data: C 12 H 26 O 2 Si; FG = 230.43
13 C-NMR (100 MHz 1 CDCl 3 ): d = 147.10 (s), 110.39 (t), 75.21 (d), 62.17 (t), 36.79 (t), 25.89 (q), 18.41 (s), - 5.49 (q), -5.53 (q)

(S)-1-[(t-Butyldimethylsilyl)oxy]-3-hydroxy-4-methyl-4-penten 11(S) -1 - [(t-butyldimethylsilyl) oxy] -3-hydroxy-4-methyl-4-pentene 11

Man löst 600 mg 2 (2.60 mmol) und 91.5 mg (-)-Diisopropyltartrat (0.391 mmol) unter N2 in 10.4 ml abs. CH2Cl2 und versetzt mit 180 mg gepulvertem, frisch aktiviertem Molsieb 4 A. Als interner Standard für die GC werden 100 ml n-Decan dazugegeben. Man kühlt auf -20°C ab und gibt unter Rühren 74 mg Titan(IV)- isopropylat (0.260 mmol) dazu. Nach 30 Min. wird ein aliquoter Teil von etwa 4 Tropfen entnommen und bei 0°C mit einer Mischung von je etwa 0.15 ml Ether und Eisen(II)-sulfat-Zitronensäure-Lösung (s. unten) aufgearbeitet. Die org. Phase dient als t0 -Probe für die GC. Man gibt 610 ml einer ca. 3 M-Lösung von t-Butylhydroperoxid in Isooctan (1.82 mmol) dazu. Die Reaktionsmischung wird im Kühlschrank bei -22°C aufbewahrt. Ein- bis zweimal täglich werden Proben entnommen und wie oben aufgearbeitet. Die jeweilige Konzentration von 11 wird gaschromatographisch bestimmt.600 mg 2 (2.60 mmol) and 91.5 mg (-) - diisopropyl tartrate (0.391 mmol) are dissolved in 10.4 ml abs under N 2 . CH 2 Cl 2 and mixed with 180 mg of powdered, freshly activated molecular sieve 4 A. 100 ml of n-decane are added as an internal standard for the GC. It is cooled to -20 ° C. and 74 mg of titanium (IV) isopropylate (0.260 mmol) are added with stirring. After 30 minutes, an aliquot of about 4 drops is removed and worked up at 0 ° C. with a mixture of about 0.15 ml of ether and iron (II) sulfate-citric acid solution (see below). The org. Phase serves as a t 0 sample for the GC. 610 ml of an approximately 3 M solution of t-butyl hydroperoxide in isooctane (1.82 mmol) are added. The reaction mixture is stored in the refrigerator at -22 ° C. Samples are taken once or twice a day and processed as above. The respective concentration of 11 is determined by gas chromatography.

Nach 118 h wird die Reaktion bei etwa 50%-iger Umsetzung von 27 abgebrochen.After 118 h, the reaction is terminated with a 50% conversion of 27.

Bei -20°C wird eine frisch angesetzte, auf 0°C gekühlte Lösung von 3.3 g Eisen(II)-sulfat-heptahydrat und 1.1 g Zitronensäuremonohydrat in 10 ml dest. Wasser dazugegeben. Nach 20 Min. kräftigem Rühren ohne weitere Kühlung wird die Mischung dreimal mit CH2Cl2 extrahiert. Die ges. org. Phasen werden auf ca. 10 ml eingeengt und bei 0°C 30 Min. lang mit 3 ml NaOH-Lsg. (30% in ges. NaCl-Lsg) gerührt. Es wird wiederum dreimal mit CH2Cl2 extrahiert, und die vereinigten org. Phasen werden mit ges. NaCl-Lsg. gewaschen, über MgSO4 getrocknet und eingeengt. Flashchromatographische Reinigung (Ether:Pentan = 1 : 6) liefert 274 mg 11 (1.19 mmol; 46% des Eduktes) als farbloses Öl.
Allgemeine Daten: C12H26O2Si; FG=230.43
(c=1, CHCl3), [a]D = -4.6°; ee = 90% (berechnet durch Integration der olefinischen 1H-NMR-Signale sowie des 1H-NMR-Signals der C-4-Methylprotonen der diastereomeren Reaktionsprodukte von 11 mit S(+)-a-Methoxy-a-trifluor- methyl­ phenylessigsäurechlorid, S(+)-MTPA-Cl).A freshly prepared, cooled to 0 ° C solution of 3.3 g iron (II) sulfate heptahydrate and 1.1 g citric acid monohydrate in 10 ml dist. Water added. After vigorous stirring for 20 minutes without further cooling, the mixture is extracted three times with CH 2 Cl 2 . The total org. Phases are concentrated to approx. 10 ml and at 0 ° C. for 30 minutes with 3 ml NaOH solution. (30% in saturated NaCl solution). It is extracted again three times with CH 2 Cl 2 , and the combined org. Phases are with sat. NaCl solution. washed, dried over MgSO 4 and concentrated. Flash chromatographic purification (ether: pentane = 1: 6) yields 274 mg 11 (1.19 mmol; 46% of the educt) as a colorless oil.
General data: C 12 H 26 O 2 Si; FG = 230.43
(c = 1, CHCl 3 ), [a] D = -4.6 °; ee = 90% (calculated by integrating the olefinic 1 H-NMR signals and the 1 H-NMR signal of the C-4-methyl protons of the diastereomeric reaction products of 11 with S (+) - a-methoxy-a-trifluoromethyl phenylacetic acid chloride, S (+) - MTPA-Cl).

Die absolute Konfiguration des überwiegenden Enantiomers wurde nach der Methode von MOSHER durch Vergleich der 1H-NMR-Spektren der Reaktionsprodukte von 11 mit S(+)-MTPA-Cl bzw. R(-)-MTPA-Cl bestimmt.The absolute configuration of the predominant enantiomer was determined by the MOSHER method by comparing the 1 H-NMR spectra of the reaction products of 11 with S (+) - MTPA-Cl and R (-) - MTPA-Cl.

(S)-3-Benzyloxy-1-[(t-butyldimethylsilyl)oxy]-4-methyl-4-penten 28(S) -3-benzyloxy-1 - [(t-butyldimethylsilyl) oxy] -4-methyl-4-pentene 28

70 mg einer Suspension von 35% Kaliumhydrid in Mineralöl (0.609 mmol) werden unter N2 mit 0.5 ml abs. THF versetzt und auf 0°C gekühlt. Man gibt 1.5 ml Benzylbromid (12.6 mmol) dazu. Unter Rühren wird eine Lösung von 117 mg 11(0.508 mmol) und 3 mg Tetra-n-butylammoniumiodid (8 mmol) in 1 ml abs. THF dazugetropft. Nach 15 Min. läßt man auf RT erwärmen. Es wird 19 h gerührt, danach werden 8 ml ges. NH4Cl-Lsg. eingespritzt. Die Mischung wird zweimal mit Ether extrahiert, die vereinigten org. Phasen werden zweimal mit ges. NaCl-Lsg. und einmal mit Wasser gewaschen und über MgSO4 getrocknet. Nach dem Einengen am Rotationsverdampfer wird der Hauptteil des noch vorhandenen Benzylbromides bei RT im Hochvakuum abgezogen. Flashchromatographische Reinigung (Ether:Petrolether = 1 : 100) liefert 96 mg 28 (0.299 mmol; 59% d.Th.) als farbloses Öl.
Allgemeine Daten: C19H32O2Si, FG=320.54
13C-NMR (100 MHz, CDCl3): d=144.70 (s), 138.87 (s), 128.33 (d), 127.78 (d), 127.40(d), 113.54(t), 80.03(d), 70.07(t), 59.71(t), 37.18(t), 25.97(q), 18.30(s), 16.75 (q), -5.28(q), -5.31(q) 70 mg of a suspension of 35% potassium hydride in mineral oil (0.609 mmol) of abs ml under N 2 with 0.5. THF added and cooled to 0 ° C. 1.5 ml of benzyl bromide (12.6 mmol) are added. A solution of 117 mg of 11 (0.508 mmol) and 3 mg of tetra-n-butylammonium iodide (8 mmol) in 1 ml of abs. THF added dropwise. After 15 minutes, the mixture is allowed to warm to RT. The mixture is stirred for 19 h, then 8 ml are sat. NH 4 Cl solution. injected. The mixture is extracted twice with ether, the combined org. Phases are recorded twice with sat. NaCl solution. and washed once with water and dried over MgSO 4 . After concentrating on a rotary evaporator, the main part of the benzyl bromide still present is removed at RT in a high vacuum. Flash chromatographic purification (ether: petroleum ether = 1: 100) yields 96 mg 28 (0.299 mmol; 59% of theory) as a colorless oil.
General data: C 19 H 32 O 2 Si, FG = 320.54
13 C-NMR (100 MHz, CDCl 3 ): d = 144.70 (s), 138.87 (s), 128.33 (d), 127.78 (d), 127.40 (d), 113.54 (t), 80.03 (d), 70.07 (t), 59.71 (t), 37.18 (t), 25.97 (q), 18.30 (s), 16.75 (q), -5.28 (q), -5.31 (q)

(S)-3-Benzyloxy-5-[(t-butyldimethylsilyl)oxy]-2-pentanon 9(S) -3-benzyloxy-5 - [(t-butyldimethylsilyl) oxy] -2-pentanone 9

Zu einer Mischung aus 1.5 ml THF und 1.5 ml Wasser werden 38 mg 28 (118 mmol) gegeben. 48 mg einer Lsg. von 2.5% OsO4 in t-Butanol (4.7 mmol) werden mit 0.5 ml THF gemischt und dazugetropft. Es wird 5 Min. gerührt; dann werden 127 mg NalO4 (590 mmol) dazugegeben. Nach 12 h kräftigem Rühren bei RT wird die Reaktionsmischung in 20 ml Ether gegossen und mit 5 ml Wasser verdünnt. Man extrahiert zweimal mit Ether, trocknet die vereinigten org. Phasen über MgSO4 und engt ein. Flashchromatographische Reinigung (Ether:Pentan = 1 : 4) liefert 14 mg 5 (43.4 mmol; 37% d.Th.) als graubraunes Öl.
Allgemeine Daten: C18H30O3Si; FG=322.53
13C-NMR (100 MHz, CDCl3): d=211.00(s), 137.67 (s), 128.51(d), 127.94(d), 127.90 (d), 82.00 (d), 72.59 (t), 58.68 (t), 35.23 (t), 25.94 (q), 25.68 (q), 18.30 (s), -5.38 (q), -5.43(q)38 mg 28 (118 mmol) are added to a mixture of 1.5 ml THF and 1.5 ml water. 48 mg of a solution of 2.5% OsO 4 in t-butanol (4.7 mmol) are mixed with 0.5 ml THF and added dropwise. The mixture is stirred for 5 minutes; then 127 mg of NalO 4 (590 mmol) are added. After vigorous stirring at RT for 12 h, the reaction mixture is poured into 20 ml of ether and diluted with 5 ml of water. It is extracted twice with ether, the combined org. Phases over MgSO 4 and concentrated. Flash chromatographic purification (ether: pentane = 1: 4) yields 14 mg 5 (43.4 mmol; 37% of theory) as a gray-brown oil.
General data: C 18 H 30 O 3 Si; FG = 322.53
13 C-NMR (100 MHz, CDCl 3 ): d = 211.00 (s), 137.67 (s), 128.51 (d), 127.94 (d), 127.90 (d), 82.00 (d), 72.59 (t), 58.68 (t), 35.23 (t), 25.94 (q), 25.68 (q), 18.30 (s), -5.38 (q), -5.43 (q)

4-Hydroxymethyl-2-methylthiazol 294-hydroxymethyl-2-methylthiazole 29

Die Verbindung 29 wird durch Ringschluß von L-Cystein-methylester-hydrochlorid mit Acetaldehyd, anschließender Dehydrierung über MnO2 und Reduktion der Methylestergruppe durch LAH hergestellt.
Allgemeine Daten: C5H7NOS; FG=129.19; CAS-Nr. [76632-23-0]
13C-NMR (50 MHz, CDCl3): d=167(s), 156.0(s), 114.4 (d), 60.5(t), 19.0 (q)Compound 29 is prepared by ring closure of L-cysteine methyl ester hydrochloride with acetaldehyde, subsequent dehydrogenation over MnO 2 and reduction of the methyl ester group by LAH.
General data: C 5 H 7 NOS; FG = 129.19; CAS number [76632-23-0]
13 C-NMR (50 MHz, CDCl 3 ): d = 167 (s), 156.0 (s), 114.4 (d), 60.5 (t), 19.0 (q)

4-Brommethyl-2-methylthiazol 304-bromomethyl-2-methylthiazole 30

Man löst 60 mg 29 (0.464 mmol) in 1 ml abs. Ether und gibt unter Rühren 47 mg Triphenylphosphin (0.511 mmol) und 169 mg Tetrabrommethan (0.511 mmol) dazu. Nach 16 h Rühren (RT) wird der Niederschlag abfiltriert und mit Ether gewaschen. Das Filtrat wird eingeengt und flashchromato-graphisch gereinigt (Ether:Pentan = 1 : 5). Man erhält 33 mg 30 (0.172 mmol; 37% d.Th.) als helles bräunliches Öl.
Allgemeine Daten: C5H6BrNS; FG=192.08
13C-NMR (100 MHz, CDCl3): d=166.91(s), 151.63(s), 117.25(d), 27.11(t), 19.25 (q) 60 mg of 29 (0.464 mmol) are dissolved in 1 ml of abs. Ether and with stirring 47 mg triphenylphosphine (0.511 mmol) and 169 mg tetrabromomethane (0.511 mmol). After stirring for 16 h (RT), the precipitate is filtered off and washed with ether. The filtrate is concentrated and purified by flash chromatography (ether: pentane = 1: 5). 33 mg of 30 (0.172 mmol; 37% of theory) are obtained as a light brownish oil.
General data: C 5 H 6 BrNS; FG = 192.08
13 C-NMR (100 MHz, CDCl 3 ): d = 166.91 (s), 151.63 (s), 117.25 (d), 27.11 (t), 19.25 (q)

Verbindung 10Connection 10

150 mg 1(0.78 mmol) und 300 ml Triethylphosphit (1.75 mmol) werden 1.5 h lang auf 160°C erhitzt. Nach dem Abkühlen wird das überschüssige Triethylphosphit im Vakuum abdestilliert. Flashchromatographische Reinigung (Ether/Methanol = 19 : 1) liefert 173 mg 2 (89% d. Th.) als schwach gelbliches Öl.
13C-NMR (100 MHz, CDCl3): d = 165.44(s), 145.96 (ds, 2J(C,P)=8.2 Hz), 115.67 (dd, 3J(C,P)=7.4 Hz), 62.19 (dt, 2 C, 2J(C,P)=6.4 Hz), 29.35 (dt, 1J(C,P)=141 Hz), 19.05 (q), 16.35 (dq, 2 C, 3J(C,P)=6.0 Hz)
(Anmerkung: Bei den zweifachen Angaben zur Signalmultiplizität bezieht sich das führende Zeichen auf die im Spektrum sichtbare durch C,P-Kopplung verursachte Multiplizität und das folgende Zeichen auf die durch C,H-Kopplung verursachte, im Standardspektrum unsichtbare Multiplizität.)150 mg 1 (0.78 mmol) and 300 ml triethyl phosphite (1.75 mmol) are heated to 160 ° C for 1.5 h. After cooling, the excess triethyl phosphite is distilled off in vacuo. Flash chromatographic purification (ether / methanol = 19: 1) yields 173 mg 2 (89% of theory) as a slightly yellowish oil.
13 C-NMR (100 MHz, CDCl 3 ): d = 165.44 (s), 145.96 (ds, 2 J (C, P) = 8.2 Hz), 115.67 (dd, 3 J (C, P) = 7.4 Hz) , 62.19 (dt, 2 C, 2 J (C, P) = 6.4 Hz), 29.35 (dt, 1 J (C, P) = 141 Hz), 19.05 (q), 16.35 (dq, 2 C, 3 J (C, P) = 6.0 Hz)
(Note: In the case of the double information on signal multiplicity, the leading symbol refers to the multiplicity visible in the spectrum caused by C, P coupling and the following symbol to the multiplicity invisible in the standard spectrum caused by C, H coupling.)

Verbindung 8Connection 8

Unter N2 werden 33 mg 2 (132 mmol) in 2 ml abs. THF gelöst und auf -78°C gekühlt. Man tropft 78 ml n-BuLi-Lsg. (15% in Hexan; 125 mmol) dazu und läßt 45 Min. rühren. Anschließend wird bei -78°C eine Lösung von 35 mg Methylketon 9 (109 mmol) in 1 ml abs. THF dazugegeben. Nach langsamer Erwärmung auf RT läßt man noch 40 h rühren und gibt dann 10 ml ges. NH4Cl-Lsg. zu der Reaktionsmischung. Es wird dreimal mit je 15 ml Ether extrahiert. Die vereinigten org. Phasen werden zweimal mit wenig Wasser und einmal mit ges. NaCl-Lsg. gewaschen. Nach dem Trocknen über MgSO4 wird das Lösungsmittel am Rotationsverdampfer abdestilliert. Flashchromatographische Reinigung (Pentan/Dichlormethan = 1 : 1, dann 1 : 2) liefert 17 mg 4 (38% d. Th.) als farbloses Öl.
13C-NMR (100 MHz, CDCl3): d = 164.4 (s), 152.90 (s), 139.74 (s), 138.84 (s), 128.33 (d, 2 C), 127.77 (d, 2 C), 127.41(d), 121.33(d), 115.67 (d), 82.00(d), 70.30 (t), 59.69 (t), 37.58 (t), 25.98 (q, 3 C), 19.26 (q), 18.30 (s), 13.44 (q), -5.25(q), -5.31 (q)Under N 2, 33 mg of 2 (132 mmol) in 2 ml of abs. THF dissolved and cooled to -78 ° C. 78 ml of n-BuLi solution are added dropwise. (15% in hexane; 125 mmol) and let stir for 45 min. A solution of 35 mg of methyl ketone 9 (109 mmol) in 1 ml of abs. THF added. After slowly warming to RT, stirring is continued for 40 h and then 10 ml of sat. NH 4 Cl solution. to the reaction mixture. It is extracted three times with 15 ml ether each. The united org. Phases are carried out twice with a little water and once with sat. NaCl solution. washed. After drying over MgSO 4 , the solvent is distilled off on a rotary evaporator. Flash chromatographic purification (pentane / dichloromethane = 1: 1, then 1: 2) yields 17 mg 4 (38% of theory) as a colorless oil.
13 C-NMR (100 MHz, CDCl 3 ): d = 164.4 (s), 152.90 (s), 139.74 (s), 138.84 (s), 128.33 (d, 2 C), 127.77 (d, 2 C), 127.41 (d), 121.33 (d), 115.67 (d), 82.00 (d), 70.30 (t), 59.69 (t), 37.58 (t), 25.98 (q, 3 C), 19.26 (q), 18.30 ( s), 13.44 (q), -5.25 (q), -5.31 (q)

Die Darstellung von 8b
The representation of 8b

erfolgt aus
takes place from

wobei der TBDMS-Ether mit Fluorid gespalten wird, der primäre Alkohol mittels Dess.-Martin-Oxidatin (Perjodat) in den Aldehyd und dieser mit dem Methylen- Wittig-Reagenz (Ph3=CH2) in die Verbindung 8b überführt wird. Die Schutzgruppe Benzyl ist beliebig gegen andere gängige Hydroxyl-Schutzgruppen austauschbar. whereby the TBDMS ether is cleaved with fluoride, the primary alcohol is converted into the aldehyde by means of Dess.-Martin oxidatin (periodate) and this is converted into the compound 8b with the methylene-Wittig reagent (Ph 3 = CH 2 ). The protective group benzyl is interchangeable with other common hydroxyl protective groups.

Darstellung von (4S,6S)-2-(2,2-dimethyl-[1,3]dioxan-4-yl)-5-hydroxy-2,4,6 trimethyl-undecan-3-on 91Preparation of (4S, 6S) -2- (2,2-dimethyl- [1,3] dioxan-4-yl) -5-hydroxy-2,4,6 trimethyl-undecan-3-one 91

Zu einer Lösung von 23 mg Diisopropylamin (0.227 mmol, leq.) in ml THF werden bei 0°C 142 γl (0.227 mmol, 1 eq.) einer 1.6 M Lösung von n-BuLi in Hexan zugetropft und 30 Minuten bei 0°C gerührt, bevor dann auf -78°C heruntergekühlt wird. Nun werden 49 mg (0.227 mmol, 1 eq.) (S)-2-(2,2-dimethyl- [1,3]dioxan-4-yl-2-methyl-pentan-3-on 3 (siehe Stammanmeldung), gelöst in 1 ml THF langsam zugetropft. Die Lösung wird 35 Minuten bei -78°C gerührt. Anschließend werden 55 mg (0.224 mmol, 099 eq.) 2-Methyl-heptanal 4a zugetropft und 1 h bei -78°C gerührt. Die Reaktionslösung wird durch Zugabe von gesättigter NH4Cl-Lösung gequenscht und auf RT erwärmt. Die wäßrige Phase wird mit Ether extrahiert, die vereinigten organischen Phasen über MgSO4 getrocknet und das Lösungsmittel am Rotationsverdampfer abdestestilliert. Der Rückstand wird säulenchromatographisch mit Pentan:Diethylether = 2 : 1 gereinigt. Man erhält 55 mg (0.107 mmol, 52%) des Aldolprodukts als farbloses Öl.
142 γl (0.227 mmol, 1 eq.) Of a 1.6 M solution of n-BuLi in hexane are added dropwise to a solution of 23 mg of diisopropylamine (0.227 mmol, leq.) In ml of THF at 0 ° C. and at 30 ° C. for 30 minutes stirred before cooling down to -78 ° C. Now 49 mg (0.227 mmol, 1 eq.) (S) -2- (2,2-dimethyl- [1,3] dioxan-4-yl-2-methyl-pentan-3-one 3 (see parent application) , dissolved in 1 ml of THF is slowly added dropwise. The solution is stirred for 35 minutes at -78 ° C. Then 55 mg (0.224 mmol, 099 eq.) 2-methyl-heptanal 4a are added dropwise and the mixture is stirred at -78 ° C. for 1 h. The reaction solution is quenched by adding saturated NH 4 Cl solution and warmed to RT, the aqueous phase is extracted with ether, the combined organic phases are dried over MgSO 4 and the solvent is distilled off on a rotary evaporator 2: 1. 55 mg (0.107 mmol, 52%) of the aldol product are obtained as a colorless oil.

Gemäß konventioneller Methoden wird der Benzyl- oder TBDMS-Ether 91 hergestellt, es können hier auch andere Hydroxylschutzgruppen, wie bereits für B offenbart, verwendet werden.
The benzyl or TBDMS ether 91 is prepared in accordance with conventional methods; other hydroxyl protecting groups, as already disclosed for B, can also be used here.

Die Stufenfolge bis 94 ist analog dem Stand der Technik, dem Fachmann also bekannt, konventionelle Schutzgruppenchemie.
The step sequence up to 94 is analogous to the prior art, that is to say to the person skilled in the art, conventional protective group chemistry.

Durch Oxidation, z. B. Pyridiniumdichromat wird die Carbonsäure 95 erhalten
By oxidation, e.g. B. pyridinium dichromate, the carboxylic acid 95 is obtained

Die Veresterung zu Verbindungen der allgemeinen Formel 2b erfolgt hier beispielsweise mit DMAP/DCCl, (Angew. Chem. 90, (1978), S. 556).
The esterification to give compounds of the general formula 2b takes place here, for example, with DMAP / DCCl, (Angew. Chem. 90, (1978), p. 556).

Für die Synthese ist besonders der Methylester 96 geeignet,
Methyl ester 96 is particularly suitable for the synthesis,

In analoger Weise lassen sich aus 80
In an analogous way, 80

wie bereits in der Stammanmeldung offenbart, die Verbindungen der allgemeinen Formel 2a
as already disclosed in the parent application, the compounds of general formula 2a

herstellen. produce.  

Die Erfindung betrifft auch Stereoisomere der Verbindungen gemäß Ansprüche 1-6, wie diese üblicherweise innerhalb der Synthese anfallen. Die Erfindung beinhaltet auch Verfahren zur Herstellung der Verbindungen gemäß Ansprüche 1-6.The invention also relates to stereoisomers of the compounds according to Claims 1-6, as they usually arise within the synthesis. The invention also includes processes for the preparation of the compounds according to Claims 1-6.

Claims (7)

1. Verbindungen der allgemeinen Formel 2a
worin
A = Wasserstoff oder eine niedrige Alkylgruppe (C1-C4) und
B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeuten.1. Compounds of the general formula 2a
wherein
A = hydrogen or a lower alkyl group (C 1 -C 4 ) and
B = hydrogen, benzyl, tetrahydropyranyl or a silyl protective group. 2. Verbindungen der allgemeinen Formel 2b
worin
A = Wasserstoff oder eine niedrige Alkylgruppe (C1-C4) und
B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeuten.2. Compounds of the general formula 2b
wherein
A = hydrogen or a lower alkyl group (C 1 -C 4 ) and
B = hydrogen, benzyl, tetrahydropyranyl or a silyl protective group. 3. Verbindungen nach Anspruch 1 oder 2, wobei die Bedeutung von B im Molekül unterschiedlich sein kann.3. Compounds according to claim 1 or 2, wherein the meaning of B can be different in the molecule. 4. 2-Methyl-6-heptenal 4a
4. 2-methyl-6-heptenal 4a
5. Verbindungen der allgemeinen Formel 8a
worin
B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeutet und die Bedeutung von B im Molekül unterschiedlich sein kann.5. Compounds of the general formula 8a
wherein
B = hydrogen, benzyl, tetrahydropyranyl or a silyl protecting group and the meaning of B in the molecule can be different. 6. Verbindungen der allgemeinen Formel 8b
worin
B = Wasserstoff, Benzyl-, Tetrahydropyranyl- oder eine Silylschutzgruppe bedeutet und die Bedeutung von B im Molekül unterschiedlich sein kann.6. Compounds of the general formula 8b
wherein
B = hydrogen, benzyl, tetrahydropyranyl or a silyl protecting group and the meaning of B in the molecule can be different. 7. Stereoisomere der Verbindungen gemäß Ansprüche 1-6.7. Stereoisomers of the compounds according to claims 1-6.
DE19645361A 1996-08-30 1996-10-28 Production of epothilone compounds with taxol-like activity Withdrawn DE19645361A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE19645361A DE19645361A1 (en) 1996-08-30 1996-10-28 Production of epothilone compounds with taxol-like activity
EP97914077A EP0923583A1 (en) 1996-08-30 1997-01-15 Method for producing epothilones, and intermediate products obtained during the production process
JP10511141A JP2001500851A (en) 1996-08-30 1997-01-15 Process for producing epothilone and intermediate products obtained during the process
PCT/DE1997/000111 WO1998008849A1 (en) 1996-08-30 1997-01-15 Method for producing epothilones, and intermediate products obtained during the production process
AU21493/97A AU716610B2 (en) 1996-08-30 1997-01-15 Method for producing epothilones, and intermediate products obtained during the production process
NZ334821A NZ334821A (en) 1996-08-30 1997-01-15 Method for producing epothilones
US08/921,512 US5969145A (en) 1996-08-30 1997-09-02 Process for the production of epothilones and intermediate products within the process
US09/344,713 US6043372A (en) 1996-08-30 1999-06-25 Intermediates in the process for preparing epothilones
US09/478,466 US6156905A (en) 1996-08-30 2000-01-06 Deoxy epothilones and intermediates utilized in the process for preparing epothilones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636343A DE19636343C1 (en) 1996-08-30 1996-08-30 New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
DE19645361A DE19645361A1 (en) 1996-08-30 1996-10-28 Production of epothilone compounds with taxol-like activity

Publications (1)

Publication Number Publication Date
DE19645361A1 true DE19645361A1 (en) 1998-04-30

Family

ID=26029142

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19645361A Withdrawn DE19645361A1 (en) 1996-08-30 1996-10-28 Production of epothilone compounds with taxol-like activity

Country Status (1)

Country Link
DE (1) DE19645361A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6316630B1 (en) 1996-12-03 2001-11-13 Sloan Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6576651B2 (en) 2001-01-25 2003-06-10 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6670384B2 (en) 2001-01-25 2003-12-30 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
US6686380B2 (en) 2001-02-20 2004-02-03 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
US6689802B2 (en) 2000-08-16 2004-02-10 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6727276B2 (en) 2001-02-20 2004-04-27 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6936628B2 (en) 2002-04-04 2005-08-30 Bristol-Myers Squibb Company Oral administration of epothilones
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7022330B2 (en) 2001-01-25 2006-04-04 Bristol-Myers Squibb Company Parenteral formulation for epothilone analogs
US7053069B2 (en) 2002-05-15 2006-05-30 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7172884B2 (en) 2002-09-23 2007-02-06 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US7244594B2 (en) 1998-12-23 2007-07-17 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7846952B2 (en) 1996-11-18 2010-12-07 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6831076B2 (en) 1995-11-17 2004-12-14 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6613912B2 (en) 1995-11-17 2003-09-02 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US7846952B2 (en) 1996-11-18 2010-12-07 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions
US8076490B2 (en) 1996-11-18 2011-12-13 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6316630B1 (en) 1996-12-03 2001-11-13 Sloan Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
USRE41990E1 (en) * 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6284781B1 (en) 1996-12-03 2001-09-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6369234B1 (en) 1996-12-03 2002-04-09 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6300355B1 (en) 1996-12-03 2001-10-09 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7750164B2 (en) 1996-12-03 2010-07-06 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8481575B2 (en) 1996-12-03 2013-07-09 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6828340B2 (en) 1996-12-03 2004-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6723854B2 (en) 1996-12-03 2004-04-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6603023B2 (en) 1996-12-03 2003-08-05 Sloan Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6656961B2 (en) 1996-12-03 2003-12-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
USRE41893E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
USRE41911E1 (en) 1997-07-08 2010-11-02 Bristol-Myers Squibb Company Epothilone derivatives
US8921542B2 (en) 1997-07-08 2014-12-30 Bristol-Myers Squibb Company Epothilone derivatives
US8536327B2 (en) 1997-07-08 2013-09-17 Bristol-Myers Squibb Company Epothilone derivatives
USRE43003E1 (en) 1997-07-08 2011-12-06 Bristol-Myers Squibb Company Epothilone derivatives
US7241755B2 (en) 1997-07-08 2007-07-10 Bristol-Myers Squibb Company Epothilone derivatives
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US7125899B2 (en) 1997-07-08 2006-10-24 Bristol-Myers Squibb Company Epothilone derivatives
USRE41895E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6831090B2 (en) 1998-04-21 2004-12-14 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US7244594B2 (en) 1998-12-23 2007-07-17 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
USRE39356E1 (en) * 2000-03-20 2006-10-17 Bristol-Myers Squibb Co. Process for the preparation of epothilone analogs
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6982276B2 (en) 2000-08-16 2006-01-03 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
USRE39251E1 (en) * 2000-08-16 2006-08-29 Bristol-Myers Squibb Co. Polymorphs of an epothilone analog
US7153879B2 (en) 2000-08-16 2006-12-26 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6689802B2 (en) 2000-08-16 2004-02-10 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6670384B2 (en) 2001-01-25 2003-12-30 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
USRE40387E1 (en) * 2001-01-25 2008-06-17 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US8632788B2 (en) 2001-01-25 2014-01-21 Bristol-Myers Squibb Company Parenteral formulation for epothilone analogs
US6576651B2 (en) 2001-01-25 2003-06-10 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US7022330B2 (en) 2001-01-25 2006-04-04 Bristol-Myers Squibb Company Parenteral formulation for epothilone analogs
US6686380B2 (en) 2001-02-20 2004-02-03 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
USRE41393E1 (en) 2001-02-20 2010-06-22 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
US6727276B2 (en) 2001-02-20 2004-04-27 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
US8569347B2 (en) 2001-03-14 2013-10-29 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US8598215B2 (en) 2001-03-14 2013-12-03 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US6936628B2 (en) 2002-04-04 2005-08-30 Bristol-Myers Squibb Company Oral administration of epothilones
US7053069B2 (en) 2002-05-15 2006-05-30 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7759374B2 (en) 2002-08-23 2010-07-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8110590B2 (en) 2002-08-23 2012-02-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8513429B2 (en) 2002-08-23 2013-08-20 Sloan-Kettering Insitute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7241899B2 (en) 2002-09-23 2007-07-10 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
USRE42191E1 (en) 2002-09-23 2011-03-01 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
US7767432B2 (en) 2002-09-23 2010-08-03 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
US7172884B2 (en) 2002-09-23 2007-02-06 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B

Similar Documents

Publication Publication Date Title
DE19645361A1 (en) Production of epothilone compounds with taxol-like activity
DE19645362A1 (en) Production of epothilone compounds with taxol-like activity
DE19636343C1 (en) New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
EP1001951B1 (en) Thiazole derivatives, method for their production and use
EP0185359B1 (en) Oxetanone
WO1998008849A1 (en) Method for producing epothilones, and intermediate products obtained during the production process
Takahashi et al. Highly stereoselective synthesis of exocyclic tetrasubstituted enol ethers and olefins. A synthesis of nileprost
WO2000000485A1 (en) Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
DE19726627A1 (en) New intermediates for epothilone
WO2005113495A1 (en) Method for producing diphenyl azetidinone derivatives
EP1682527B1 (en) Method for the production of statins
EP1161430A2 (en) Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
WO2006122644A2 (en) Method for the production of statins
Holt et al. Synthesis of β-1-homonojirimycin and β-1-homomannojirimycin using the enzyme aldolase
DE60222244T2 (en) PROCESS FOR PREPARING INTERCONNECTIONS IN THE MANUFACTURE OF DISCODERMOLID AND DISCODERMOLID ANALOGUE
WO2003053949A1 (en) C1-c6 fragments of epothilones and method for producing such fragments and the derivatives thereof
Davies et al. Synthesis of γ-lactones from intermediate 2-(γ-hydroxyacyl)-imidazoles by N-methylation and base-catalyzed C C bond cleavage. Application to the synthesis of (±)-cavernosine
EP0766660A1 (en) Cyclohexanone derivatives, method of preparing them and intermediates used in the method
Kazmaier et al. A short synthesis of polyhydroxylated piperidines by aldol reaction of chelated amino acid ester enolates
DE19735578A1 (en) New di:hydroxy-hexanone or -pentene derivatives
WO1999014210A1 (en) Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
Michelet et al. A New Synthetic Approach Toward (+)‐Ambruticin Analogs: Preparation of a C10–C11 cis‐Isomer Fragment
DE19735574A1 (en) New 3-hydroxy-5-oxo-hexanoic acid derivatives
DE19735575A1 (en) New di:hydroxy-butanal or -pentene derivatives
Durst et al. Carbanions derived from 3-methoxyazetidinones: precursors for the preparation of 3, 3-disubstituted azetidinones

Legal Events

Date Code Title Description
AF Is addition to no.

Ref country code: DE

Ref document number: 19636343

Format of ref document f/p: P

8181 Inventor (new situation)

Free format text: SCHINZER, DIETER, 38108 BRAUNSCHWEIG, DE LIMBERG, ANJA, 38102 BRAUNSCHWEIG, DE BOEHM, OLIVAR M., 38118 BRAUNSCHWEIG, DE BAUER, ARMIN, 38106 BRAUNSCHWEIG, DE CORDES, MARTIN, 38106 BRAUNSCHWEIG, DE

8130 Withdrawal